within Pharmacolibrary.Drugs.ATC.C;

model C09DB05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 6.5e-05,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.053,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 1200,            
    Vdp             = 0.04,
    k12             = 35,
    k21             = 35
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09DB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Irbesartan and amlodipine is a fixed-dose combination medication used for the treatment of hypertension. Irbesartan is an angiotensin II receptor blocker (ARB), while amlodipine is a calcium channel blocker; together, they lower blood pressure and reduce cardiovascular risk. Both drugs are widely approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for healthy adult subjects after oral administration, based on known individual PK of irbesartan and amlodipine and cross-referenced summary data of combination products.</p><h4>References</h4><ol><li><p>Frampton, JE, &amp; Scott, LJ (2009). Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. <i>American journal of cardiovascular drugs : drugs, devices, and other interventions</i> 9(5) 309–330. DOI:<a href=\"https://doi.org/10.2165/11201120-000000000-00000\">10.2165/11201120-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19791840/\">https://pubmed.ncbi.nlm.nih.gov/19791840</a></p></li><li><p>Scott, LJ, &amp; McCormack, PL (2008). Olmesartan medoxomil: a review of its use in the management of hypertension. <i>Drugs</i> 68(9) 1239–1272. DOI:<a href=\"https://doi.org/10.2165/00003495-200868090-00005\">10.2165/00003495-200868090-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18547134/\">https://pubmed.ncbi.nlm.nih.gov/18547134</a></p></li><li><p>McClellan, KJ, &amp; Jarvis, B (2000). Lercanidipine: a review of its use in hypertension. <i>Drugs</i> 60(5) 1123–1140. DOI:<a href=\"https://doi.org/10.2165/00003495-200060050-00009\">10.2165/00003495-200060050-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11129125/\">https://pubmed.ncbi.nlm.nih.gov/11129125</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09DB05;
